Management of Heart Failure in Elderly Patients

Evidence-Based Rationale

The American Society of Nephrology and European Heart Journal recommend that in elderly patients with heart failure, amlodipine should be discontinued while lisinopril, an ACE inhibitor, must be continued and optimized, as ACE inhibitors are foundational mortality-reducing therapy in HF, whereas amlodipine increases heart failure hospitalizations and provides no survival benefit 1, 2, 3
ACE inhibitors like lisinopril reduce all-cause mortality and cardiovascular death in heart failure patients, with benefits demonstrated across all age groups including the elderly, according to the European Heart Journal and European Journal of Heart Failure 2, 4
The European Society of Cardiology guidelines position calcium channel blockers as last-line agents for blood pressure control in HF, to be added only after ACE inhibitors, beta-blockers, and diuretics 6, 7

The European Heart Journal recommends that elderly patients with heart failure should be maintained on adequate ACE inhibitor doses rather than very low doses unless intolerance occurs 2
Amlodipine significantly increases heart failure hospitalizations by 38% in the ALLHAT study, making it detrimental in established HF, as reported in the Journal of the American Society of Nephrology 1
Dihydropyridine calcium channel blockers like amlodipine neither improve nor worsen survival in HF patients, providing no mortality benefit, according to Circulation 3
Amlodipine should only be used in HF for refractory hypertension after all other guideline-directed medical therapies have been optimized and failed, not as routine therapy, as stated in Circulation 3

The American College of Cardiology recommends ensuring the patient is on a beta-blocker for additional mortality benefit 2, 4, 5
The European Heart Journal suggests adding or optimizing aldosterone antagonist therapy if not contraindicated by renal function or hyperkalemia 2, 4
Loop diuretics should be used for volume management in elderly patients due to reduced glomerular filtration rate, as recommended by the European Heart Journal 6, 7, 8

Renal function and electrolytes should be rechecked within 10 days of medication changes, as elderly patients are at higher risk for hyperkalemia with ACE inhibitors, especially when combined with aldosterone antagonists, according to the European Heart Journal 6, 7, 5
Orthostatic hypotension should be assessed within 10 days of medication changes, as reported in the European Heart Journal 7, 8
Symptom improvement and signs of congestion should be evaluated within 10 days of medication changes, as recommended by Praxis Medical Insights 8

The European Heart Journal recommends starting ACE inhibitor dose adjustments with smaller increments and longer titration periods compared to younger patients 7, 5
Relief of symptoms may be a more important goal than life prolongation for some elderly patients, but this does not justify withholding proven mortality-reducing therapies, as stated in the European Heart Journal 6, 8